Lake Street Raises Price Target on AVITA Medical, Inc. (RCEL) to $3.50, Maintains Hold Rating

Company Overview - AVITA Medical, Inc. (NASDAQ:RCEL) is a regenerative medicine company focused on developing and commercializing innovative therapeutic solutions for complex wound and tissue repair [4] Financial Performance - The company has guided for FY26 revenue of $80 million to $85 million, an increase from $71.6 million in FY24, indicating a positive growth outlook [3] - Recent debt refinancing has alleviated near-term liquidity concerns, contributing to a healthier balance sheet [1] Strategic Focus - Management emphasized that the past year was dedicated to stabilizing revenue, advancing the clinical pipeline, and improving financial flexibility, laying the groundwork for future growth [3] - AVITA Medical is transitioning into a phase of execution-led growth, supported by upcoming clinical and commercial milestones [3][4] Analyst Insights - Lake Street raised its price target on AVITA Medical to $3.50 from $3 while maintaining a Hold rating, indicating cautious optimism about the company's future performance [1]